Search

08/08/2024 Evolving trends in neuropsychological profiles of post COVID-19 condition: A 1-year follow-up in individuals with cognitive complaints
Grunden, N, Calabria, M, García-Sánchez, C, Pons, C, Arroyo, JA, Gómez-Ansón, B, Estévez-Garcia, MD, Belvís, R, Morollón, N, Cordero-Carcedo, M, Mur, I, Pomar, V, Domingo, P. Evolving trends in neuropsychological profiles of post COVID-19 condition: A 1-year follow-up in individuals with cognitive complaints. PLoS One. 2024; 19(8)DOI:10.1371/journal.pone.0302415. PMID:39116061. IF:2.600(Q2/4D).
01/04/2024 Appropriate Duration of Antimicrobial Treatment for Prosthetic Joint Infections: A Narrative Review
Lora-Tamayo, J, Mancheño-Losa, M, Meléndez-Carmona, MA, Hernández-Jiménez, P, Benito, N, Murillo, O. Appropriate Duration of Antimicrobial Treatment for Prosthetic Joint Infections: A Narrative Review. Antibiotics-Basel. 2024; 13(4)DOI:10.3390/antibiotics13040293. PMID:38666969. IF:4.600(Q1/2D).
01/03/2026 Anifrolumab in systemic lupus erythematosus: real-world evidence from a Spanish multicentre cohort of 206 patients and literature review
Calvo-Río, V, Secada-Gómez, C, Gutiérrez, AM, Retuerto-Guerrero, M, Font, J, Casafont-Solé, I, Mayo-Juanatey, A, Sancho, JJA, Freites, D, Hormigos, C, Puñal, NG, Arribas, GG, Sanchez, JRM, García-Valle, A, Ibañez, M, Morillo, FL, Manzanares, AG, Sandoval-Moreno, S, Cortes-Hernandez, J, Sanchez, DP, Lojo, L, Pérez, ECC, Collado, P, Larios, CA, Icardo, LS, Labrador-Sánchez, E, Peralta-Ginés, C, Onaindia, IU, Plaza-Aulestia, N, Malone, MM, de Salazar, JRG, Corteguera, M, Cebrián-Méndez, L, Pages, FAA, Riazuelo, JRL, Canales, MDF, Hernández, MJA, Bufort, MG, Pàmies, A, de Ardanaz, LS, Aguirre-del-Pino, R, Lefler, JAC, Seijas-Lopez, A, Cubero, MDC, Cofiño, ALC, Ortiz-Santamaria, V, Piñeiro, ML, Calvo, CO, Lopez, CA, Urruticoechea-Arana, A, Magallon, BG, Alfaro, AVA, Rodriguez, SL, Olivares, MS, Villar, PL, Brandy-García, AM, Vilamajo, IR, Martos, AG, Lopez, BPM, Urmeneta, GS, Martín, CC, Riera, E, Bejerano, C, Castañeda, S, Blanco, R. Anifrolumab in systemic lupus erythematosus: real-world evidence from a Spanish multicentre cohort of 206 patients and literature review. RMD Open. 2026; 12(1)DOI:10.1136/rmdopen-2025-006549. PMID:41856562. IF:4.700(Q1/1D).
01/03/2026 B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment
Agmon-Levin, N, Ignatenko, S, Gordienko, A, Cortés-Hernández, J, Narongroeknawin, P, Romanowska-Próchnicka, K, Shen, N, Ciferska, H, Kodera, M, Cheng-Chung, WJ, Leszczynski, P, Lan, JL, Mysler, E, Wojciechowski, R, Tarr, T, Vishneva, E, Chen, YH, Kaneko, Y, Finzel, S, Hoi, A, Okada, M, Koolvisoot, A, Lee, SS, Lie, D, Kaneko, H, Rojkovich, B, Sun, LY, Zotkin, E, Viallard, JF, López, BPM, Ghanshani, SA, Lau, C, Avrameas, A, Sips, C, Oliver, SJ. B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment. ANNALS OF THE RHEUMATIC DISEASES. 2026; 85(3)DOI:10.1016/j.ard.2025.11.015. PMID:41353079. IF:20.600(Q1/1D).